Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow.
Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, Stojdl DF, Daneshmand M, Speth K, Kirn D, McCart JA, Atkins H, Bell JC.
Breitbach CJ, et al.
Mol Ther. 2007 Sep;15(9):1686-93. doi: 10.1038/sj.mt.6300215. Epub 2007 Jun 19.
Mol Ther. 2007.
PMID: 17579581
Free article.